Back Back
Cell No. : Cell Name
RCB1200 : MMAc·SF  update : 2022/08/24
CommentSerum-free medium-adapted MMAc cells. For SF culture, + insulin, hEGF, hydrocortisone, bovine pituit
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (
Basic information Depositor Katayama, Hiroshi
Originator Katayama, Hiroshi
Year of deposit 1996
Animal _human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Female
Age at sampling 39 years
Tissue melanoma, ascites meta
Metastatic ability Yes
Metastatic tissue liver, lymph node et
Classification cancer
Year of origin 1995
Lifespan infinite
Morphology other
Cellosaurus(Expasy) CVCL_1420
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Culture medium HuMedia-KG2
Antibiotics Free
Passage method 0.25% Trypsin, added HuMedia-KG2 + 10%FBS, washed twice with HuMedia-KG2
Culture information Passage ratio 1 : 3-4 split
SC frequency Subculture : once/10 days, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium HuMedia : 2 x FM1 = 1 : 1
Freezing method Slow freezing
Mycoplasma (-)
Isozyme LD, NP
Chromosome mode 69-80(16) : /72(1),72(2),74(1),75(2),76(3),77(3)/
STR(human) OK
deposit info
lot info
Reference information Reference 0
User's Publication 4

To topTop

To topTop
User's Publication
20812  Comandante-Lou N, Baumann DG, Fallahi-Sichani M.  AP-1 transcription factor network explains diverse patterns of cellular plasticity in melanoma cells.  Cell Rep  2022  40(5)  PubMed ID: 35926467   DOI: 10.1016/j.celrep.2022.111147
18107  Comandante-Lou N, Khaliq M, Venkat D, Manikkam M, Fallahi-Sichani M.  Phenotype-based probabilistic analysis of heterogeneous responses to cancer drugs and their combination efficacy   PLoS Comput Biol  2020  16(2):e1007688  PubMed ID: 32084135   DOI: 10.1371/journal.pcbi.1007688
13309  Gerosa L, Chidley C, Fröhlich F, Sanchez G, Lim SK, Muhlich J, Chen JY, Vallabhaneni S, Baker GJ, Schapiro D, Atanasova MI, Chylek LA, Shi T, Yi L, Nicora CD, Claas A, Ng TSC, Kohler RH, Lauffenburger DA, Weissleder R, Miller MA, Qian WJ, Wiley HS, Sorger PK.  Receptor-Driven ERK Pulses Reconfigure MAPK Signaling and Enable Persistence of Drug-Adapted BRAF-Mutant Melanoma Cells.  Cell Syst  2020    PubMed ID: 33113355   DOI: 10.1016/j.cels.2020.10.002
14264  Ward GA, Lewis EJ, Ahn JS, Johnson CN, Lyons JF, Martins V, Munck JM, Rich SJ, Smyth T, Thompson NT, Williams PA, Wilsher NE, Wallis NG, Chessari G.  ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth  Mol Cancer Ther  2018  17(7):1381-1391  PubMed ID: 29695633   DOI: 10.1158/1535-7163.MCT-17-0848

Back Back Return Top Page